C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of “Hold” by Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been given an average rating of “Hold” by the six analysts that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several equities analysts have weighed in on CCCC shares. Stephens started coverage on C4 Therapeutics in a research report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 target price for the company. BMO Capital Markets restated an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a report on Tuesday, August 6th.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $4.55 on Monday. C4 Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $11.88. The company has a 50 day moving average price of $5.48 and a 200 day moving average price of $5.58. The stock has a market capitalization of $321.18 million, a P/E ratio of -2.68 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The business had revenue of $15.36 million during the quarter, compared to analysts’ expectations of $5.95 million. Research analysts forecast that C4 Therapeutics will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC purchased a new stake in C4 Therapeutics during the second quarter worth approximately $45,000. B. Riley Wealth Advisors Inc. acquired a new stake in C4 Therapeutics during the second quarter worth approximately $51,000. Point72 DIFC Ltd acquired a new stake in C4 Therapeutics during the third quarter worth approximately $51,000. Cynosure Group LLC purchased a new stake in shares of C4 Therapeutics during the 3rd quarter worth approximately $57,000. Finally, Aigen Investment Management LP acquired a new position in shares of C4 Therapeutics in the 3rd quarter valued at $82,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.